Chief Commercial Officer · OptimizeRx Corp (OPRX)

Theresa Greco

FY2025 is the first fiscal year CompBrief holds for Theresa Greco as a named executive officer of OptimizeRx; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,544,265

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Theresa Greco compensation by year

OptimizeRx Summary Compensation Table · the one fiscal year held
In US dollars, as OptimizeRx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$367,500
Bonus$0
Stock awards$353,182
Option awards$409,312
Non-equity incentive$398,471
Pension and deferred compensation$0
All other$15,800
Total$1,544,265

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OptimizeRx Corp DEF 14A filed April 30, 2026, accession 0001213900-26-049698, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU15,625$191,563—
RSU10,352$126,916—
RSU7,042$86,335—
RSU6,173$75,681—
RSU2,441$29,927—
Option11,920—$8.10
Option19,436—$4.83
Option12,133—$10.65
Option35,156—$16.14

Per the Outstanding Equity Awards at Fiscal Year-End table in OptimizeRx Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed April 30, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-15Tax withholding—914$5.2171,954
2026-05-15Tax withholding—879$5.2171,075

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

OptimizeRx’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Stephen SilvestroChief Executive Officer$2,717,717
Theresa Greco · this pageChief Commercial Officer$1,544,265
Edward StelmakhChief Financial & Strategy Officer$1,524,170

The full OptimizeRx compensation record

free company brief

This page is one person within OptimizeRx's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order OptimizeRx's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OptimizeRx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy